Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 5/20 | 0.67 |
| ▸ | CPT2 | P23786 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2968025 | 0.98 | ACLY (0.64) | ACLYCPT2ALDH1A1HSPD1BLM | |
| SCHEMBL31683881 | 0.96 | ACLY (0.67) | ACLYCPT2ALDH1A1HSPD1BLM | |
| Potassium Ion SCHEMBL2966018 | 0.88 | CPT2 (0.50) | ACLYCPT2ALDH1A1TET2 | |
| Potassium Ion SCHEMBL2966012 | 0.88 | ACLY (0.50) | ACLYCPT2ALDH1A1HSPD1BLM | |
| Water SCHEMBL2961261 | 0.86 | ACLY (0.48) | ACLYCPT2ALDH1A1HSPD1BLM | |
| Water SCHEMBL2964495 | 0.86 | CPT2 (0.48) | ACLYCPT2 | |
| SCHEMBL31683880 | 0.83 | CPT2 (0.50) | ACLYCPT2ALDH1A1TET2 | |
| Water SCHEMBL30996783 | 0.81 | ACLY (0.91) | ACLYCPT2ALDH1A1HSPD1BLM | |
| SCHEMBL721435 | 0.80 | ACLY (1.00) | ACLYCPT2ALDH1A1HSPD1BLM | |
| SCHEMBL17181757 | 0.80 | ACLY (1.00) | ACLYCPT2ALDH1A1HSPD1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042814-A1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH & HUMAN SERVICES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-3784774-B1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | US HEALTH (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12415845-B2 | Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-09-16 | — | — | US | disclosed |
| CN-118726256-A | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-10-01 | — | — | CN | disclosed |
| CN-112262212-B | Methods of producing T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2024-07-12 | — | — | CN | disclosed |
| CN-115006378-A | Medicine for preventing or treating metabolic diseases or metabolic dysfunction diseases | 西安莱格瑞生物科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-112262212-A | Methods of generating T cell populations using hydroxycitric acid and/or salts thereof | 美国卫生和人力服务部 | 2021-01-22 | — | — | CN | disclosed |
| US-7772428-B2 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | Northern Innovations and Formulations (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20080300309-A1 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals | NEW CELL FORMULATIONS LTD (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1846368-A4 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | NEW HC FORMULATIONS LTD (CA) | 2008-01-23 | — | — | EP | disclosed |
| EP-1846368-A1 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | New HC Formulations Ltd. (CA) | 2007-10-24 | — | — | EP | disclosed |
| US-20060194877-A1 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | NEW CELL FORMULATIONS LTD. (CA) | 2006-08-31 | — | — | US | disclosed |
| WO-2006081682-A1 | CREATINE HYDROXYCITRIC ACIDS SALTS AND METHODS FOR THEIR PRODUCTION AND USE IN INDIVIDUALS | NEW CELL FORMULATIONS LTD. (CA) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194877-A1 | Creatine hydroxycitric acids salts and methods for their production and use in individuals | CKMT1A; CKMT1B, GYS1, PYGM | ACLY 62/4885CPT2 152/4885ALDH1A1 3301/4885 |
| US-20260042814-A1 | METHODS OF PRODUCING T CELL POPULATIONS USING HYDROXYCITRIC ACID AND/OR A SALT THEREOF | NFATC1, SLC9A1, NHERF1 | ACLY 3175/4885CPT2 648/4885ALDH1A1 2087/4885 |
| US-20080300309-A1 | Creatine Hydroxycitric Acids Salts and Methods for their Production and use in Individuals | CKMT1A; CKMT1B, GYS1, PYGM | ACLY 62/4885CPT2 152/4885ALDH1A1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.